← Leaderboards
Katharine C Hsu
Sloan-Kettering Inst Can Research
$29,362,365
Attributed
$30,568,899
Total exposure
14
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.2M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$29,219,154 · 12
FDA$1,349,745 · 2
By mechanism
R01$15,282,433 · 8
T32$12,825,403 · 2
P01$1,509,073 · 2
K23$645,723 · 1
R56$306,267 · 1
Top collaborators
- Shakeel Modak9 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Raymond J Muller$2,385,467
- Shakeel Modak$2,048,034
- Brian Shaffer$631,908
- Sean Devlin$993,097
Others in their field
Top investigators on “Natural Killer Cells”
- Barton F Haynes · Duke University$112,979,211
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Craig B Thompson · Sloan-Kettering Inst Can Research$42,638,329
- Selwyn M Vickers · University Of Alabama At Birmingham$41,029,054
- James C. Paulson · Scripps Research Institute$39,353,775
Research focus
Natural Killer CellsAllogenicCellsResponseReceptorImmune SystemLeukemiaRelapseT-LymphocyteImmuneMalignant NeoplasmsLigandsTransplant RecipientsIn VivoIn VitroMediatingVirus DiseasesExhibitsBone Marrow TransplantationTransplantationAllograftingLicensingGenotypeEnvironment
Grant awards (51)
Weill Cornell/Rockefeller/Sloan Kettering MST Program$2,041,076
T32 · FY2025 · GM · contact PI
HCMV-induced innate-like CD8 T cells and allogeneic HCT outcome$688,546
R01 · FY2025 · AI · contact PI
Weill Cornell/Rockefeller/Sloan Kettering MST Program$2,517,309
T32 · FY2024 · GM · contact PI
HCMV-induced innate-like CD8 T cells and allogeneic HCT outcome$709,841
R01 · FY2024 · AI · contact PI
Machine learning with immunogenetics for the prediction of hematopoietic cell transplant outcomes$583,984
R01 · FY2024 · HL · contact PI
Weill Cornell/Rockefeller/Sloan Kettering MST Program$2,837,865
T32 · FY2023 · GM · contact PI
HCMV-induced innate-like CD8 T cells and allogeneic HCT outcome$733,090
R01 · FY2023 · AI · contact PI
Machine learning with immunogenetics for the prediction of hematopoietic cell transplant outcomes$595,903
R01 · FY2023 · HL · contact PI
Weill Cornell/Rockefeller/Sloan Kettering MST Program$2,794,772
T32 · FY2022 · GM · contact PI
HCMV-induced innate-like CD8 T cells and allogeneic HCT outcome$709,841
R01 · FY2022 · AI · contact PI
Machine learning with immunogenetics for the prediction of hematopoietic cell transplant outcomes$608,405
R01 · FY2022 · HL · contact PI
Weill Cornell/Rockefeller/Sloan Kettering MST Program$2,634,381
T32 · FY2021 · GM · contact PI
HCMV-induced innate-like CD8 T cells and allogeneic HCT outcome$759,700
R01 · FY2021 · AI · contact PI
Machine learning with immunogenetics for the prediction of hematopoietic cell transplant outcomes$650,223
R01 · FY2021 · HL · contact PI
Project 3: NK and T cell cooperation in CMV infection$4,029
P01 · FY2021 · CA · contact PI
KIR and HLA in cis and trans cooperatively shape human NK education$449,000
R01 · FY2020 · AI · contact PI
Project 3: NK and T cell cooperation in CMV infection$8,562
P01 · FY2020 · CA · contact PI
Selection of Allogeneic Hematopoietic Cell Donor Based on KIR and HLA Genotypes$480,567
R01 · FY2019 · HL · contact PI
KIR and HLA in cis and trans cooperatively shape human NK education$428,500
R01 · FY2019 · AI · contact PI
Phase I study humanized 3F8 MoAb (IND 112594) and NK cells (IND BB-13399) for neuroblastoma$249,917
R01 · FY2019 · FD · contact PI
Selection of Allogeneic Hematopoietic Cell Donor Based on KIR and HLA Genotypes$541,616
R01 · FY2018 · HL · contact PI
KIR and HLA in cis and trans cooperatively shape human NK education$428,500
R01 · FY2018 · AI · contact PI
Selection of Allogeneic Hematopoietic Cell Donor Based on KIR and HLA Genotypes$573,445
R01 · FY2017 · HL · contact PI
KIR and HLA in cis and trans cooperatively shape human NK education$428,500
R01 · FY2017 · AI · contact PI
Natural killer cell and T-cell crosstalk in CMV infection$306,267
R56 · FY2017 · AI · contact PI
NK Receptor Function in Hematopoietic Stem Cell Transplantation$275,113
P01 · FY2017 · CA · contact PI
Phase I study humanized 3F8 MoAb (IND 112594) and NK cells (IND BB-13399) for neuroblastoma$249,829
R01 · FY2017 · FD · contact PI
Selection of Allogeneic Hematopoietic Cell Donor Based on KIR and HLA Genotypes$550,116
R01 · FY2016 · HL · contact PI
KIR and HLA in cis and trans cooperatively shape human NK education$428,500
R01 · FY2016 · AI · contact PI
NK Receptor Function in Hematopoietic Stem Cell Transplantation$307,650
P01 · FY2016 · CA · contact PI
Phase I study humanized 3F8 MoAb (IND 112594) and NK cells (IND BB-13399) for neuroblastoma$250,000
R01 · FY2016 · FD · contact PI
Selection of Allogeneic Hematopoietic Cell Donor Based on KIR and HLA Genotypes$420,982
R01 · FY2015 · HL · contact PI
NK Receptor Function in Hematopoietic Stem Cell Transplantation$307,650
P01 · FY2015 · CA · contact PI
Combination immunotherapy for neuroblastoma: model of innate tumor immunity$354,947
R01 · FY2014 · CA · contact PI
NK Receptor Function in Hematopoietic Stem Cell Transplantation$298,420
P01 · FY2014 · CA · contact PI
Phase 1 Study of Immunotherapy with NK Cells anti-GD2 for Neuroblastoma$199,999
R01 · FY2014 · FD · contact PI
Combination immunotherapy for neuroblastoma: model of innate tumor immunity$343,969
R01 · FY2013 · CA · contact PI
NK Receptor Function in Hematopoietic Stem Cell Transplantation$307,649
P01 · FY2013 · CA · contact PI
Phase 1 Study of Immunotherapy with NK Cells anti-GD2 for Neuroblastoma$200,000
R01 · FY2013 · FD · contact PI
NK Tolerance and Hematopoietic Cell Transplantation$416,543
R01 · FY2012 · HL · contact PI
Combination immunotherapy for neuroblastoma: model of innate tumor immunity$364,407
R01 · FY2012 · CA · contact PI
Phase 1 Study of Immunotherapy with NK Cells anti-GD2 for Neuroblastoma$200,000
R01 · FY2012 · FD · contact PI
NK Tolerance and Hematopoietic Cell Transplantation$420,750
R01 · FY2011 · HL · contact PI
NK Tolerance and Hematopoietic Cell Transplantation$420,750
R01 · FY2010 · HL · contact PI
NK Tolerance and Hematopoietic Cell Transplantation$420,750
R01 · FY2009 · HL · contact PI
NK Tolerance and Hematopoietic Cell Transplantation$421,313
R01 · FY2008 · HL · contact PI
NK Receptors and Bone Marrow Transplant Outcome$129,223
K23 · FY2008 · HL · contact PI
NK Receptors and Bone Marrow Transplant Outcome$129,223
K23 · FY2007 · HL · contact PI
NK Receptors and Bone Marrow Transplant Outcome$129,223
K23 · FY2006 · HL · contact PI
NK Receptors and Bone Marrow Transplant Outcome$128,983
K23 · FY2005 · HL
NK Receptors and Bone Marrow Transplant Outcome$129,071
K23 · FY2004 · HL